LARGE Aneurysm Randomized Trial: Flow Diversion Versus Traditional Endovascular Coiling Therapy (LARGE)
Primary Purpose
Intracranial Aneurysm
Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Flow Diversion
Coiling
Sponsored by
About this trial
This is an interventional treatment trial for Intracranial Aneurysm focused on measuring Aneurysm, Coiling, Flow Diversion
Eligibility Criteria
Inclusion criteria
- Age 21 to 75 years, inclusive
Patient has a single target IA that: is located in the following regions of the internal carotid artery:
- Paraophthalmic (including paraclinoid, ophthalmic and hypophyseal segments)
- Cavernous
- Petrous
- has a parent vessel with diameter 2.5-5.0 mm
- Wide neck aneurysm ≥4 mm.
- Target IA has size (maximum fundus diameter) 10 mm
- The operator feels that the aneurysm can be appropriately treated with traditional endovascular techniques (endovascular coil embolization with or without adjunctive devices or parent artery deconstruction) using endovascular coiling or flow diversion devices.
- Modified Rankin Scale 0-3
- Signed and dated informed consent
4.2 Exclusion criteria
- More than one IA requiring treatment in the next 6 months
- Subarachnoid hemorrhage in the past 60 days
- Any intracranial hemorrhage in the last 42 days
- Major surgery (requiring general anesthesia) in the last 42 days
- Coils in place in the target IA
- Unstable neurologic deficit (i.e., any rapidly worsening clinical condition in the last 30 days (defined by a change in mRS of 2 or more))
- Known irreversible bleeding disorder
- Platelet count < 100 x 103 cells/mm3 or known platelet dysfunction
- Clinically documented evidence in medical history of adverse reaction or contraindication to medications used in treatment of the aneurysm (i.e. Plavix, heparin, aspirin)
- Prior stent placement at target site
- Documented history of dementia
- Contraindication to CT scan and MRI (ie. contrast allergy, or other condition that prohibits imaging from either CT or MRI)
- Known allergy to contrast used in angiography that cannot be medically controlled
- Known severe allergy to platinum or cobalt/chromium alloys
- Relative contraindication to angiography (e.g., serum creatinine > 2.5 mg/dL)
- Pregnancy, breast-feeding, or positive pregnancy test [either serum or urine] (Woman of child-bearing potential must have a negative pregnancy test prior to the study procedure.)
- Evidence of active infection (indicated by fever [at or over 99.9 °F] and/or open draining wound) at the time of randomization
- Other known conditions of the heart, blood, brain or intracranial vessels that carry a high risk of neurologic events (e.g., severe heart failure, atrial fibrillation, known carotid stenosis)
- Current use of cocaine or other illicit substance
- Any comorbid disease or condition expected to compromise survival or ability to complete Follow-up assessments through 180 days
- Extracranial stenosis greater than 50% in the carotid artery
- Intracranial stenosis greater than 50% in the treated vessel
- Based on investigator's judgment, patient does not have the necessary mental capacity to participate or is unwilling or unable to comply with protocol follow up appointment schedule.
- "Previously randomized into this trial or currently participating in another trial where the data is intended to be used to obtain marketing approval or to broaden an indication, without the approval of the study principal investigator, that may confound the results of this study.
A screen failure log of all cases referred or presented for possible inclusion, but who were not randomized, and the reason(s) for exclusion will be maintained.
Sites / Locations
- MUSC
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Coiling
Flow Diversion
Arm Description
Coiling
Flow Diversion
Outcomes
Primary Outcome Measures
The primary aim of aneurysm treatment is to achieve occlusion of the IA without morbidity or mortality.
Greater than 90% angiographic occlusion AND stable (or decreased) aneurysm size on cross sectional imaging (CT or MR) at 180 days post procedure. The primary objective is to show that flow diversion is non-inferior to endovascular coiling with respect to a combined efficacy and safety endpoint.
Secondary Outcome Measures
Incidence of device or procedure related adverse events at 180 days, 1 year and 3 years.
a count of the occurrences of device related Adverse Events will be recorded and compared between randomized groups at 90, 180, 1year, 2 year, and 3 year time points.
Subgroup analysis of clinical and angiographic outcomes in aneurysms 10-20 mm and > 2 cm.
A comparison will be made as a subgroup analysis of clinical and angiographic outcomes in aneurysms 10-20 mm and > 2 cm. will be measured based on efficacy (Greater than 90% angiographic occlusion AND stable (or decreased) aneurysm size on cross sectional imaging (CT or MR) at 180 days post procedure) and Safety (Free of any major neurologic event (defined as change in NIHSS from baseline > 4 points) downstream from target aneurysm, or death at 180 days post procedure) within this subgroup of study patients.
Downstream flow related ischemic stroke, parenchymal hemorrhage, subarachnoid hemorrhage, aneurysm rupture or re-treatment of index aneurysm rates at 180 days, one year and 3 years.
A count of occurrences of downstream flow related ischemic stroke, parenchymal hemorrhage, subarachnoid hemorrhage, aneurysm rupture or re-treatment of index aneurysm rates at 180 days, one year and 3 years. will be measured and compared at each time point: 180 days, 1 year, and 3 year between groups
Change in clinical functional outcome at 180 days, 1 year and 3 years post-endovascular treatment procedure, as measured by an increase in the modified Rankin Scale from baseline.
A comparison between groups will be conducted of change in modified rankin scale. The comparison will be measured by an increase in the modified Rankin Scale from baseline, change in clinical functional outcome at 180 days, 1 year and 3 years post-endovascular treatment procedure, as measured by an increase in the modified Rankin Scale from baseline.
Incidence of worsening of baseline neurological signs/symptoms as measured by NIHSS/ophthalmologist exam related to target intracranial aneurysm (IA) at 180 days.
A count and comparison of the incidence of worsening of baseline neurologic signs/symptoms as measured by national institutes of health stroke scale (NIHSS) or ophthalmological exam related to target IA at 180 days will be made between groups.
Number of inpatient hospital (and re-hospitalized) days (subgrouped >7 days) at 180 days, 1 year and 3 years.
A count and comparison of the number of inpatient hospital (and re-hospitalized) days (subgrouped >7 days) at 180 days, 1 year and 3 years will be performed between groups
Packing density as measured by volumetric filling of the aneurysm if aneurysm is coiled.
An analysis of packing density as measured by volumetric filling of the aneurysm if aneurysm is coiled will be performed. The analysis will show within group relationships and possible correlations among coiled patients and other variables.
Device cost of therapy at treatment and any subsequent retreatment.
Device cost of therapy at treatment and any subsequent retreatment will be counted and compared between groups in the study.
Procedure time, as measured as the time from placement of the treating guide catheter for purposes of aneurysm treatment until guide catheter removal.
Procedure time, as measured as the time from placement of the treating guide catheter for purposes of aneurysm treatment until guide catheter removal, will be collected, measured and compared between groups in the study.
Subgroup analysis of clinical and angiographic outcomes in aneurysms intradural vs. extradural location
A comparison will be made as a subgroup analysis of clinical and angiographic outcomes in aneurysms of intradural vs. extradural location and will be measured based on efficacy (Greater than 90% angiographic occlusion AND stable (or decreased) aneurysm size on cross sectional imaging (CT or MR) at 180 days post procedure) and Safety (Free of any major neurologic event (defined as change in NIHSS from baseline > 4 points) downstream from target aneurysm, or death at 180 days post procedure) within this subgroup of study patients.
Subgroup analysis of clinical and angiographic outcomes in aneurysms reconstructive vs. deconstructive technique.
A comparison will be made as a subgroup analysis of clinical and angiographic outcomes in aneurysms treated with reconstructive vs. deconstructive technique and will be measured based on efficacy (Greater than 90% angiographic occlusion AND stable (or decreased) aneurysm size on cross sectional imaging (CT or MR) at 180 days post procedure) and Safety (Free of any major neurologic event (defined as change in NIHSS from baseline > 4 points) downstream from target aneurysm, or death at 180 days post procedure) within this subgroup of study patients.
Full Information
NCT ID
NCT01762137
First Posted
November 16, 2012
Last Updated
February 9, 2018
Sponsor
Medical University of South Carolina
1. Study Identification
Unique Protocol Identification Number
NCT01762137
Brief Title
LARGE Aneurysm Randomized Trial: Flow Diversion Versus Traditional Endovascular Coiling Therapy
Acronym
LARGE
Official Title
LARGE Aneurysm Randomized Trial: Flow Diversion Versus Traditional Endovascular Coiling Therapy
Study Type
Interventional
2. Study Status
Record Verification Date
February 2018
Overall Recruitment Status
Terminated
Why Stopped
Rarity of disease and current practice in the field made enrollment challenging.
Study Start Date
February 2013 (undefined)
Primary Completion Date
February 2017 (Actual)
Study Completion Date
February 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of South Carolina
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In this study, patients with large anterior circulation IAs with neck and fundus morphologies amenable to either traditional endovascular treatments using coils or reconstruction with the flow diversion will be randomly assigned to either treatment technique.
Detailed Description
This is a prospective, randomized trial comparing the endovascular coiling (endovascular coiling) versus the flow diversion for large and giant aneurysm treatment. The endovascular coiling used in this study are FDA-approved and in common use at institutions in this country and across the world. The flow diversion devices are FDA-approved for anterior circulation aneurysms >10 mm and are in common use at institutions in this country and across the world. Patients will be enrolled who meet the inclusion criteria and consent to participate. Patients will be randomly assigned by a central web-based system in a 1:1 manner to treatment with either endovascular coiling or flow diversion. Data on each patient will be collected at the time of enrollment and treatment, and at subsequent follow-up visits.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intracranial Aneurysm
Keywords
Aneurysm, Coiling, Flow Diversion
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
23 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Coiling
Arm Type
Active Comparator
Arm Description
Coiling
Arm Title
Flow Diversion
Arm Type
Active Comparator
Arm Description
Flow Diversion
Intervention Type
Procedure
Intervention Name(s)
Flow Diversion
Intervention Description
Endovascular flow diverter placement
Intervention Type
Procedure
Intervention Name(s)
Coiling
Intervention Description
Endovascular coil placement
Primary Outcome Measure Information:
Title
The primary aim of aneurysm treatment is to achieve occlusion of the IA without morbidity or mortality.
Description
Greater than 90% angiographic occlusion AND stable (or decreased) aneurysm size on cross sectional imaging (CT or MR) at 180 days post procedure. The primary objective is to show that flow diversion is non-inferior to endovascular coiling with respect to a combined efficacy and safety endpoint.
Time Frame
approaximately 180 days after aneurysm treatement procedure
Secondary Outcome Measure Information:
Title
Incidence of device or procedure related adverse events at 180 days, 1 year and 3 years.
Description
a count of the occurrences of device related Adverse Events will be recorded and compared between randomized groups at 90, 180, 1year, 2 year, and 3 year time points.
Time Frame
approximately 90 days, 180 days, 1 year, 2 year and 3 year
Title
Subgroup analysis of clinical and angiographic outcomes in aneurysms 10-20 mm and > 2 cm.
Description
A comparison will be made as a subgroup analysis of clinical and angiographic outcomes in aneurysms 10-20 mm and > 2 cm. will be measured based on efficacy (Greater than 90% angiographic occlusion AND stable (or decreased) aneurysm size on cross sectional imaging (CT or MR) at 180 days post procedure) and Safety (Free of any major neurologic event (defined as change in NIHSS from baseline > 4 points) downstream from target aneurysm, or death at 180 days post procedure) within this subgroup of study patients.
Time Frame
approximately 3 years after aneurysm treatment procedure
Title
Downstream flow related ischemic stroke, parenchymal hemorrhage, subarachnoid hemorrhage, aneurysm rupture or re-treatment of index aneurysm rates at 180 days, one year and 3 years.
Description
A count of occurrences of downstream flow related ischemic stroke, parenchymal hemorrhage, subarachnoid hemorrhage, aneurysm rupture or re-treatment of index aneurysm rates at 180 days, one year and 3 years. will be measured and compared at each time point: 180 days, 1 year, and 3 year between groups
Time Frame
approaximately 180 days, 1 year, and 3 years after aneurysm treatement procedure
Title
Change in clinical functional outcome at 180 days, 1 year and 3 years post-endovascular treatment procedure, as measured by an increase in the modified Rankin Scale from baseline.
Description
A comparison between groups will be conducted of change in modified rankin scale. The comparison will be measured by an increase in the modified Rankin Scale from baseline, change in clinical functional outcome at 180 days, 1 year and 3 years post-endovascular treatment procedure, as measured by an increase in the modified Rankin Scale from baseline.
Time Frame
180 days, 1 year and 3 years post-endovascular treatment procedure
Title
Incidence of worsening of baseline neurological signs/symptoms as measured by NIHSS/ophthalmologist exam related to target intracranial aneurysm (IA) at 180 days.
Description
A count and comparison of the incidence of worsening of baseline neurologic signs/symptoms as measured by national institutes of health stroke scale (NIHSS) or ophthalmological exam related to target IA at 180 days will be made between groups.
Time Frame
180 days
Title
Number of inpatient hospital (and re-hospitalized) days (subgrouped >7 days) at 180 days, 1 year and 3 years.
Description
A count and comparison of the number of inpatient hospital (and re-hospitalized) days (subgrouped >7 days) at 180 days, 1 year and 3 years will be performed between groups
Time Frame
180 days, 1 year and 3 years.
Title
Packing density as measured by volumetric filling of the aneurysm if aneurysm is coiled.
Description
An analysis of packing density as measured by volumetric filling of the aneurysm if aneurysm is coiled will be performed. The analysis will show within group relationships and possible correlations among coiled patients and other variables.
Time Frame
after initial procedure, day 0
Title
Device cost of therapy at treatment and any subsequent retreatment.
Description
Device cost of therapy at treatment and any subsequent retreatment will be counted and compared between groups in the study.
Time Frame
approximately 6 years after the initial procedure
Title
Procedure time, as measured as the time from placement of the treating guide catheter for purposes of aneurysm treatment until guide catheter removal.
Description
Procedure time, as measured as the time from placement of the treating guide catheter for purposes of aneurysm treatment until guide catheter removal, will be collected, measured and compared between groups in the study.
Time Frame
approximately 6 years after the initial procedure
Title
Subgroup analysis of clinical and angiographic outcomes in aneurysms intradural vs. extradural location
Description
A comparison will be made as a subgroup analysis of clinical and angiographic outcomes in aneurysms of intradural vs. extradural location and will be measured based on efficacy (Greater than 90% angiographic occlusion AND stable (or decreased) aneurysm size on cross sectional imaging (CT or MR) at 180 days post procedure) and Safety (Free of any major neurologic event (defined as change in NIHSS from baseline > 4 points) downstream from target aneurysm, or death at 180 days post procedure) within this subgroup of study patients.
Time Frame
approximately 3 years after aneurysm treatment procedure
Title
Subgroup analysis of clinical and angiographic outcomes in aneurysms reconstructive vs. deconstructive technique.
Description
A comparison will be made as a subgroup analysis of clinical and angiographic outcomes in aneurysms treated with reconstructive vs. deconstructive technique and will be measured based on efficacy (Greater than 90% angiographic occlusion AND stable (or decreased) aneurysm size on cross sectional imaging (CT or MR) at 180 days post procedure) and Safety (Free of any major neurologic event (defined as change in NIHSS from baseline > 4 points) downstream from target aneurysm, or death at 180 days post procedure) within this subgroup of study patients.
Time Frame
approximately 3 years after aneurysm treatment procedure
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria
Age 21 to 75 years, inclusive
Patient has a single target IA that: is located in the following regions of the internal carotid artery:
Paraophthalmic (including paraclinoid, ophthalmic and hypophyseal segments)
Cavernous
Petrous
has a parent vessel with diameter 2.5-5.0 mm
Wide neck aneurysm ≥4 mm.
Target IA has size (maximum fundus diameter) 10 mm
The operator feels that the aneurysm can be appropriately treated with traditional endovascular techniques (endovascular coil embolization with or without adjunctive devices or parent artery deconstruction) using endovascular coiling or flow diversion devices.
Modified Rankin Scale 0-3
Signed and dated informed consent
4.2 Exclusion criteria
More than one IA requiring treatment in the next 6 months
Subarachnoid hemorrhage in the past 60 days
Any intracranial hemorrhage in the last 42 days
Major surgery (requiring general anesthesia) in the last 42 days
Coils in place in the target IA
Unstable neurologic deficit (i.e., any rapidly worsening clinical condition in the last 30 days (defined by a change in mRS of 2 or more))
Known irreversible bleeding disorder
Platelet count < 100 x 103 cells/mm3 or known platelet dysfunction
Clinically documented evidence in medical history of adverse reaction or contraindication to medications used in treatment of the aneurysm (i.e. Plavix, heparin, aspirin)
Prior stent placement at target site
Documented history of dementia
Contraindication to CT scan and MRI (ie. contrast allergy, or other condition that prohibits imaging from either CT or MRI)
Known allergy to contrast used in angiography that cannot be medically controlled
Known severe allergy to platinum or cobalt/chromium alloys
Relative contraindication to angiography (e.g., serum creatinine > 2.5 mg/dL)
Pregnancy, breast-feeding, or positive pregnancy test [either serum or urine] (Woman of child-bearing potential must have a negative pregnancy test prior to the study procedure.)
Evidence of active infection (indicated by fever [at or over 99.9 °F] and/or open draining wound) at the time of randomization
Other known conditions of the heart, blood, brain or intracranial vessels that carry a high risk of neurologic events (e.g., severe heart failure, atrial fibrillation, known carotid stenosis)
Current use of cocaine or other illicit substance
Any comorbid disease or condition expected to compromise survival or ability to complete Follow-up assessments through 180 days
Extracranial stenosis greater than 50% in the carotid artery
Intracranial stenosis greater than 50% in the treated vessel
Based on investigator's judgment, patient does not have the necessary mental capacity to participate or is unwilling or unable to comply with protocol follow up appointment schedule.
"Previously randomized into this trial or currently participating in another trial where the data is intended to be used to obtain marketing approval or to broaden an indication, without the approval of the study principal investigator, that may confound the results of this study.
A screen failure log of all cases referred or presented for possible inclusion, but who were not randomized, and the reason(s) for exclusion will be maintained.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Aquilla Turk, DO
Organizational Affiliation
Medical University of South Carolina
Official's Role
Principal Investigator
Facility Information:
Facility Name
MUSC
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
12. IPD Sharing Statement
Learn more about this trial
LARGE Aneurysm Randomized Trial: Flow Diversion Versus Traditional Endovascular Coiling Therapy
We'll reach out to this number within 24 hrs